Home » Blog » ECJC client IGXBio files Investigational New Drug (IND) Application with the FDA

ECJC client IGXBio files Investigational New Drug (IND) Application with the FDA

IGXBio, Inc., a client company of the Enterprise Center of Johnson County (ECJC), has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA). IGXBio has also been a portfolio company of Mid-America Angels since 2006.

The worldwide demand for effective therapeutic DNA-based HIV vaccines, such as GenePro®  is intense, as it is anticipated they can be used to provide Structured Therapeutic Interruption (STI) from current Highly Active Antiretroviral Therapies (HAART). Physicians can take their HIV patients off current drug treatment while substituting a therapeutic vaccine. In order to allow this, GenePro®, generates viral like particles that are effective in “waking up” the immune system, thus letting the body detect virus and stop proliferation to AIDS. FDA-approved human trials are needed to bear this out.

The ECJC has provided consulting and administrative services for IGXBio since its inception in 2001 and applauds the company for reaching this milestone.

Leave a Reply

Your email address will not be published.